Pembrolizumab in advanced rare cancers

Background null Patients with rare cancers account for 25% of cancer-related deaths but have limited treatment options. As immunotherapy has potential applicability across cancer types, we conducted an open-label phase II trial of pembrolizumab in patients with advanced rare cancers. null null null Methods null Eligible patients who had progressed on standard therapies in the last 6 months were enrolled in 9 tumor-specific cohorts and in a 10th...